NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
+6 more ↓
57%
Finnrick rating
#416 of 457 ranked vendors
174 of 290 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Nexaph's strongest purity-focus evidence is in GHK-Cu, with Retatrutide and Tirzepatide improving recently after earlier purity and fill outliers. The record is dispersed: Semaglutide, Tesamorelin, and CJC-1295 remain weak from repeated purity or identity/quantity failures, and batch-ID gaps temper an otherwise current, high-volume dataset.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Corporate records, RDAP data and site emails trace Nexaph through a fragmented operator identity rather than a clean public counterparty. The report maps sister-brand infrastructure, COA-cloning pathways and a certification/payment layer that changes buyer recourse.

31 pages8 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
89%
11
2
Tirzepatide
$1.13
76%
62
3
Retatrutide
$2.46
74%
103
4
PT-141
-
71%
3
5
Ipamorelin
$1.30
60%
10
6
BPC-157
$1.51
60%
19
7
Cagrilintide
$3.50
50%
13
8
TB-500
$1.61
38%
6
9
Tesamorelin
$2.88
37%
30
10
Sermorelin
-
37%
3
11
Semaglutide
$1.90
36%
15
12
CJC-1295
$2.78
30%
8
13
NAD+
$0.04
28%
3
14
MOTS-c
$1.88
23%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%25 May 2026: 57%27 May 2026: 56%1 Jun 2026: 56%1 Jun 2026: 56%2 Jun 2026: 56%6 Jun 2026: 56%12 Jun 2026: 57%12 Jun 2026: 57%12 Jun 2026: 57%12 Jun 2026: 57%15 Jun 2026: 57%15 Jun 2026: 57%16 Jun 2026: 57%16 Jun 2026: 57%26 Jun 2026: 57%26 Jun 2026: 57%26 Jun 2026: 58%1 Jul 2026: 57%1 Jul 2026: 57%13 Jul 2026: 57%17 Jul 2026: 57%20 Jul 2026: 57%21 Jul 2026: 57%4 Aug 2026: 57%9 Aug 2026: 57%13 Aug 2026: 57%27 Aug 2026: 57%4 Sep 2026: 57%9 Sep 2026: 57%10 Sep 2026: 57%10 Sep 2026: 57%10 Sep 2026: 57%14 Sep 2026: 57%15 Sep 2026: 57%16 Sep 2026: 57%16 Sep 2026: 57%18 Sep 2026: 57%20 Sep 2026: 57%24 Sep 2026: 57%24 Sep 2026: 57%7 Oct 2026: current 57%57%57%57%May 26Oct 26
Free peptide testing

Ordered peptides from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
Nexaph test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
24 Sep 2026
Pass
BPC-157
lab nameView COA
24 Sep 2026
Pass
Tirzepatide
lab nameView COA
20 Sep 2026
Fail
Tirzepatide
lab nameView COA
18 Sep 2026
Pass
BPC-157
lab nameView COA
16 Sep 2026
Pass
Retatrutide
lab nameView COA
16 Sep 2026
Pass
Tesamorelin
lab nameView COA
15 Sep 2026
Pass
Retatrutide
lab nameView COA
14 Sep 2026
Fail
Cagrilintide
lab nameView COA
10 Sep 2026
Pass
Tirzepatide
lab nameView COA
10 Sep 2026
Fail
Tesamorelin
lab nameView COA
1-10 of 200

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 291 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are BPC-157 (19 tests) and Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply